In this presentation, Lumos Diagnostics and nanoComposix explore technological advances in next generation nanoparticles, assay chemistries, and reader devices to improve the performance of rapid point-of-care (POC) tests.
The cardiac biomarker, Troponin has been used as a model assay to demonstrate how the sensitivity of lateral flow tests can be extended towards the limits of antibody affinity. The presentation will describe how the combination of the latest assay and reader developments can push the boundaries of sensitivity and quantification and challenge preconceived limitations of rapid POC testing.
Lumos Diagnostics Supports the Victorian Healthcare System by Providing FebriDx® for a Pilot Evaluation in the Triaging of Acute Respiratory Infection Patients
Lumos Diagnostics supports the Victorian healthcare system by providing FebriDx® for a pilot evaluation in the triaging of acute respiratory infection patients